Frontlight ResearchEarly access
SuspendedPhase 1
Phase I/II clinical trial of autologous hematopoietic stem cell gene therapy in rag1-deficient severe combined immunodeficiency
Key facts
- Who runs it
- Videja B.V.
- Where
- Italy, Netherlands, Poland, and Spain4 sites in 4 countriesChoose a country to see its sites
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 6 people, planned
- Started
- 23 Jul 2021
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 19 November 2025
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- RAG1-deficient SCID as confirmed by genetic analysis
- Peripheral blood T cells < 300/μL and/or naïve T cells < 1/μL
- Age < 2 years
- Age at least 8 weeks by the time of busulfan and fludarabine administration
- Lack of an available HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ) allele-matched (un)related donor)
- Signed informed consent (parental or guardian)
- Able to return to the local HSCT centre for follow-up (per protocol) during the 2-year study and the 15-year long-term off study review
- Absence of peripheral blood naïve CD4+ T cells
Who cannot take part
- Previous allogeneic HSCT
- Omenn syndrome
- Significant organ dysfunction/co-morbidity (including but not limited to): Mechanical ventilation, Shortening fraction on echocardiogram <25%, Renal failure defined as dialysis dependence, uncontrolled seizure disorder.)
- Any other condition that the investigator considers is a contraindication to collection and/or infusion of transduced cells for that individual or indicate patient's inability to follow the protocol, for example contraindication f to busulfan, major congenital abnormalities, ineligible to receive anaesthesia, or documented refusal or inability of the family to return for scheduled visits
- Human immunodeficiency virus (HIV) infection or Human T-cell Leukemia Virus (HTLV) infection
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the effect of RAG1 gene therapy on overall survival To evaluate the efficacy of RAG1 gene therapy in achieving reconstitution of the T and B cell immune system in patients with RAG1-SCID at 6 months To evaluate the safety and tolerability of the RAG1 gene therapy product, including identification of short- and long-term adverse events
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 19 November 2025